# Mesoblast Limited (MESO)

> Source: Nexqual · https://nexqual.com/MESO · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Mesoblast Limited (MESO), nexqual.com/MESO" · informational, not investment advice.

**Price:** USD 13.95 (+1.16% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 13.79 · day 13.5–14 · 52w 13.05–21.5 · market cap $1.81B · NMS

## Key facts
- Analysts: Strong Buy (mean 1.33 on a 1–5 scale) (3 analysts), mean target USD 37 (range 35–39).
- Total return with dividends: 1Y -22.9% vs S&P 500 +18.1%; 5Y +22.8% vs S&P 500 +85.1%.
- Next earnings: 2026-08-26, EPS estimate USD -0.08, revenue estimate $54.9M.

## Analysts
Consensus Strong Buy (mean 1.33 on a 1–5 scale), 3 analysts; mean target USD 37 (low 35, high 39).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-27 | Piper Sandler | Target raised | Overweight | $35 → $39 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | -22.9% | +22.8% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -22.9% | +4.2% |
| Volatility (annualized) | 53.9% | 85.3% |
| Max drawdown | -37.1% (Jan 2026→Jun 2026) | -86.1% (Nov 2021→Jan 2024) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/MESO · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt